An Industry Perspective: Oncology Strategy, Opportunity Assessment and R&D Decision Making | Events

As Head of Lifecycle and Pipeline at AstraZeneca, Benjamin leads a large senior division responsible for several core global assignments spanning clinical trial and portfolio investment decisions for oncology assets and provides all workflows strategic at asset tumors and above assets and pan-portfolio parameter prioritization. This includes ideation and development of new opportunities, asset appraisals, market and opportunity assessments, market research, competitor analysis, asset profiling, trial design, new standards of evaluation and mapping of care. The department also supports all licensing, research and evaluation, co-development and business development offerings and leads advisory boards and strategic coverage of medical congresses.

Benjamin is a key member of several AZ leadership and governance committees, including the Early Stage Products Committee, the Oncology Research Council Committee, and the Forecast Review Committee.

In 2021, Benjamin also joined the Department of Cancer and Surgery at Imperial College as an Honorary Principal Investigator where he lectures on oncology strategy, clinical trial design, forecasting and commercialization. drugs as part of the MRes cancer biology course.

Benjamin holds an Honors BSc in Biochemistry from Imperial College and a PhD from University College London.

The talk will include an overview of oncology market dynamics and sizing, forecasting principles, asset (drug) valuation, and marketing considerations.